Answers are grounded in this paper and cite their sources.
Review explores metabolic-PTM relationship in cancer, suggesting new therapeutic avenues for personalized medicine.
Metabolic reprogramming is a cardinal hallmark of cancer that, beyond fulfilling bioenergetic demands, generates a diverse array of intermediate metabolites—including acetyl-CoA, lactate, palmitoyl-CoA, succinyl-CoA, and NAD + —serving as active covalent donors for post-translational modifications (PTMs). This review systematically explores the metabolic-PTM nexus in cancer, elucidating how dysregulated glycolysis, lipid metabolism, the TCA cycle, and amino acid metabolism drive an expanding spectrum of modifications including acetylation, lactylation, palmitoylation, myristoylation, succinylation, and ADP-ribosylation. We examine how these metabolite-mediated PTMs regulate critical oncoproteins such as p53, Myc, GPX4, PD-L1 and cGAS, thereby governing cancer hallmarks spanning cell survival, ferroptosis resistance, and immune evasion. Furthermore, we dissect the extensive PTM crosstalk that creates a combinatorial “protein language” dynamically orchestrating tumor responses to microenvironmental cues. Emerging therapeutic strategies exploiting this interface—including metabolic substrate restriction, PTM enzyme modulation, and rational combination regimens with immunotherapy—are critically evaluated. Finally, we highlight unresolved questions regarding tissue-specific effects, non-histone targets, and detection technologies, and propose future directions toward personalized medicine based on metabolic-PTM profiling. This review reconceptualizes cancer as a disease of aberrant metabolite-driven protein regulation, illuminating a dynamic and reversible regulatory layer that offers transformative therapeutic opportunities.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: